Harding, J. J., Strickler, J. H., Henry, J., Sharma, M. R., Koganemaru, S., Passhak, M., … Geva, R. (2025). 2214MO Phase I basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC). In Annals of Oncology (Vol. 36, pp. S1145–S1145). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.2831

Harding, J. J., J. H. Strickler, J. Henry, M. R. Sharma, S. Koganemaru, M. Passhak, D. Mahalingam, et al. “2214MO Phase I basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC).” In Annals of Oncology, 36:S1145–S1145. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.2831.

Harding JJ, Strickler JH, Henry J, Sharma MR, Koganemaru S, Passhak M, et al. 2214MO Phase I basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC). In: Annals of Oncology. Elsevier BV; 2025. p. S1145–S1145.

Harding, J. J., et al. “2214MO Phase I basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC).” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S1145–S1145. Crossref, doi:10.1016/j.annonc.2025.08.2831.

Harding JJ, Strickler JH, Henry J, Sharma MR, Koganemaru S, Passhak M, Mahalingam D, Golan T, Papadopoulos KP, Hubert A, Badu-Nkansah A, Burns M, Li RR, Blaney ME, Alshaer M, Mehibel M, Geva R. 2214MO Phase I basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC). Annals of Oncology. Elsevier BV; 2025. p. S1145–S1145.